Introduction
Chronic myeloid leukaemia (CML) is a clonal disorder of the haematopoietic system resulting in the excessive accumulation of immature and mature myeloid cells. The cytogenetic hallmark of CML is the Philadelphia chromosome (Ph), resulting from the translocation of Abl on chromosome 9 to Bcr on chromosome 22 . This fusion of Bcr-Abl generates a chimeric onco-protein and is present in over 95% of CML cases, and in approximately 15% of acute lymphoblastic leukaemia (ALL) patients. The Bcr-Abl onco-protein exhibits constitutive tyrosine kinase activity and is believed to be the critical determinant in the pathogenesis of CML. 1 The clinical disorder presents initially as an indolent phase (chronic phase) characterised by the accumulation of mature myeloid cells that can be successfully controlled with relatively mild therapeutic agents (hydroxy-urea or interferon alpha). The phenotype of the disease inevitably progresses to blast crisis (CML-BC) (in the absence of stem cell transplantation). CML-in myeloid blast crisis (BC) resembles acute myeloid leukaemia (AML) where cells lose the capacity to terminally differentiate but in contrast to the majority of de novo AML, secondary AML derived from CML, exhibits profound anti-apoptotic features which is reflected in the difficulty of treatment. The drug resistance associated with CML progression to blast crisis, and consequent treatment failure in BC-CML are not well-defined.
Secondary abnormalities have been suggested to contribute to the progression of BC-CML. Duplication of the Ph chromosome represents the most frequent karyotypic abnormality in BC-CML. 2 In addition, an increase in Bcr-Abl mRNA has been associated with disease progression. 3 Interferon-alpha is currently the treatment of choice for chronic phase CML patients 4 and has been reported to down-modulate intracellular BcrAbl gene expression in vitro and in vivo. 5, 6 Indeed, patients in remission or relapse have been reported to express decreased or increased Bcr-Abl protein levels/cells, respectively. 7 Other non-random secondary abnormalities in CML karyotypes include trisomy 8 or 19 and iso-chromosome 17q. In contrast to other leukaemias, ras and myc mutations are infrequent in CML. The most common secondary mutation associated with the progression of chronic phase CML to blast crisis is alteration of the p53 gene. 8 p53 is a tumour suppressor gene which can promote cell cycle arrest and apoptosis in response to oncogene deregulation or DNA damage. 9 Loss of p53 is a feature of many other malignancies and is frequently associated with a poor prognosis.
Chronic phase CML generally retains growth factor dependence, 10 drug sensitivity and wild-type (WT) p53 suggesting that the tumor suppressor activity of p53 may restrain progression of the disease. This possibility is also supported by in vivo models of CML. P53 knockout mice infected with a Bcr-Abl expressing retrovirus develop a much more aggressive CML compared to P53 +/+ mice, 11 and p53 heterozygous mice which develop BC like CML have often lost the WT allele. 12 Such studies have demonstrated the co-operation between Bcr-Abl expression and loss of p53 in generating a fully transformed phenotype. Thus, loss of p53 in a subset of CML patients may play a role in the blastic transformation and the development of a drug-resistant disease. However, as loss of p53 only occurs in ෂ25% of patients, 13 other mechanisms must contribute to disease progression and drug resistance in CML.
Bcr-Abl has been attributed anti-apoptotic activity, as it can prevent apoptosis of factor-dependent cell lines following growth factor withdrawal, and confer resistance to apoptosis induced by DNA damage. [14] [15] [16] A number of studies have also reported that Bcr-Abl and/or v-abl can upregulate anti-apoptotic proteins such as Bcl-2 17 or Bcl-xL. 18, 19 Although such studies indicate that Bcr-Abl can provide anti-apoptotic features to cell lines, the anomaly remains that Bcr-Abl is present at both chronic phase and blast crisis CML, yet the drug sensitivity at these two phases bears no resemblance. While secondary abnormalities in other genes could contribute to disease progression, the almost universal achievement of drug resistance in blast crisis suggests that it is fundamentally related to the presence of Bcr-Abl. Recent studies have therefore begun to investigate the biological and physiological significance of elevated Bcr-Abl expression, as this is often a feature of advanced disease. It is also notable that CML immortal Leukemia cell lines (derived from BC-CML), often contain multiple copies or amplification of the Bcr-Abl gene. 20 A study of Bcr-Abl expression in a factor-dependent cell line has suggested that low levels of Bcr-Abl do not confer growth factor independence, in contrast to higher levels which also exhibit drug resistance and higher tumorigenicity in in vivo models. 21 Another study has also suggested that high levels of Bcr-Abl are required before drug resistance can be achieved and this correlated with increased Bcl-2 expression. 22 The question of whether or not elevated Bcr-Abl expression can contribute to aggressive disease is currently of fundamental importance as a novel inhibitor of the tyrosine kinase activity of Bcr-Abl (STI571) enters phase II (which include chronic phase and blast crisis phase patients) and phase III (newly diagnosed chronic phase patients) clinical trials.
In this study we have examined the consequences of elevated expression of Bcr-Abl. High and low Bcr-Abl expression confers growth factor independence and elevates Bcl-xL expression. We have also assessed the ability of STI571 to promote apoptosis, in high and low Bcr-Abl expressors and to co-operate with other cytotoxic agents in inducing apoptosis. In addition, we investigated the relationship between levels of Bcr-Abl expression, drug sensitivity, and pro-apoptotic gene expression. Our results show that in cells expressing a relatively low level of Bcr-Abl, induction of apoptosis is associated with elevation of p53, and either expression or repression of genes which are associated with a p53-mediated tumour suppressor response (Bcl-2, Bax and p21). 23, 24 In contrast, cells expressing high levels of Bcr-Abl are drug resistant and continue slowly to cycle, despite constant elevation of proapoptotic modulators. Our results suggest that high expression of Bcr-Abl appears to have a greater influence on susceptibility to apoptosis than apoptotic modulators previously associated with drug resistance in Bcr-Abl expressing cells.
Materials and methods

Cell culture
The murine myeloid 32D cell line was maintained in RPMI 1640, 10% fetal calf serum (FCS), 1% penicillin-streptomycin (P/S) (Gibco BRL, Paisley, UK), and 10% WEHI conditioned media (WEHI-CM) as a source of IL-3. Bcr-Abl transformed 32D cells (32Db2a2), were cloned by serial dilution in media containing 15% FCS and 1.7 g/ml puromycin (Sigma-Aldrich, Dublin, Ireland). Two representative clones expressing high and low levels of Bcr-Abl (C4 and C2, respectively) were selected and chosen for further study. The clones were maintained in RPMI 1640, 10% FCS, 1% P/S and 0.2 g/ml puromycin. 32D cells were transfected with pBABE Puro empty vector by electroporation, selected in 1.7 g/ml puromycin, and maintained in 10% FCS, 10% WEHI-CM, 1% P/S and 0.2 g/ml puromycin. Trypan blue exclusion assay was used to determine cell viability and cell number using a Neubauer haemocytometer.
Cell lysis and immunoblotting
Antibodies used were anti-c-Abl (ab-3) and anti-Waf-1 (p21, Ab-6) (Calbiochem, Darmstadt, Germany), anti-p53 (ab-7; Oncogene Research Products, Nottingham, UK), anti-Bcl-2 (Santa Cruz, San Diego, CA, USA), anti-Bax (Upstate Biotechnology, Lake Placid, NY, USA), anti-phosphotyrosine (PY20) and anti-Bcl-xL (Transduction Laboratories, San Diego, CA, USA). Cells were lysed in modified RIPA buffer (50 mm TrisHCl (pH 7.4), 1% Igepal, 0.25% sodium deoxycholate, 150 mm NaCl, 1 mm EDTA, 1 mm Na 3 VO 4 , 1 mm NaF, 1 g/ml antipain, 1 g/ml aprotonin, 1 g/ml chymostatin, 0.1 g/ml leupeptin, 1 g/ml pepstatin and 100 m PMSF). Equivalent amounts of protein were resolved using SDS-PAGE and transferred to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). All secondary antibodies were peroxidase conjugated and proteins were detected using enhanced chemiluminescence (ECL) (Amersham, Little Chalfont, UK). Membranes were stripped in 10 ml of 62.5 mm Tris, 2% SDS, pH 6.7 and 70 l ␤-mercaptoethanol for 30 min at 50°C.
Assessment of cell death and viability
Cell viability and apoptosis was assessed by propidium iodide (PI) uptake on a FACScan (Becton Dickinson, Oxford, UK) flow cytometer at 590 (FL-2) nm. Cells were incubated with 5 g/ml PI at room temperature (RT) prior to analysis. The criteria for cell death as measured by flow cytometry were based on changes in light scattering properties of dead cells due to cell shrinkage and increased granularity and also permeability to PI. Apoptotic cells were verified using standard morphological criteria following cytospin preparations.
Dual measurement of cell cycle and apoptosis
This was performed by measuring apoptosis using in situ terminal deoxy-uridine (dUTP) nick-end labelling (TUNEL) with subsequent PI staining of the DNA. Cells were fixed in 1% paraformaldehyde and stored overnight in 70% ethanol. After washing in PBS, cells were resuspended in 50 l of reaction mixture containing 0.1 mm dithiothreitol (DTT), 0.05 mg/ml BSA, 0.25 U/l terminal deoxynucleotidyl transferase, 0.2 mm bio-16-dUTP and 2.5 mm CoCl 2 in 0.1 m Na cacodylate (pH 7.0) buffer. This was incubated at 37°C for 30 min, washed, and resusupended in 100 l of staining buffer containing 2.5 mg/ml fluoresceinated avidin (avidin-FITC), 4 × concentrated saline-sodium citrated buffer (0.3 m), 0.1% Triton X-100 and 5% (w/v) low-fat dried milk, for 30 min at RT. Cells were then incubated in PBS containing 200 g/ml DNase free RNase A and 20 g/ml PI at RT for 30 min. Fluorescence due to FITC and PI was measured at 530 (FL-1) and 590 (FL-2) nm, respectively, on a Becton Dickinson FACScan. Single cell populations were gated on FL2-W (width) and FL2-A (area) to exclude fluorescence due to cell doublets/triplicates. Analysis of apoptotic populations and cell cycle phase was performed using CellQuest software (Becton Dickinson). Apoptosis was assessed by increased FL-1 fluorescence due to FITC staining and/or sub-G1 DNA content.
Induction of apoptosis
For IL-3 neutralisation, 32D cells were resuspended in media containing 0% or 10% WEHI-CM, and various concentrations of the IL-3 neutralising antibody (R&D Systems, Oxon, UK). Cell viability was assessed by PI uptake. Cells were treated with the cytotoxic drugs etoposide (5 g/ml VP16; Sigma, Dublin, Ireland) and doxorubicin (0.3 g/ml; Sigma). Due to the inherent fluorescent properties of doxorubicin, all FACS data shown are performed with etoposide. Doxorubicin results were confirmed by cytospin preparations. Samples were analysed every 12 h, for cell death and cell cycle arrest. Cells were treated with various concentrations of STI571 (previously CGP57148B), kindly provided by Novartis (Basel, Switzerland), to inhibit the kinase activity of Bcr-Abl. Cells were incubated in the presence of STI571 for 10 min prior to the addition of etoposide, and at 24 h were analysed for cell death by PI uptake, and apoptosis confirmed by morphology. Ten per cent WEHI-CM was added to cells in addition to STI571 and incubated for 24 h.
Proliferation assays
All cells were incubated at 3-4 × 10 5 /well in a 96-well plate, in the presence or absence of anti-IL-3 antibody (1.5 g/ml) and 1 Ci/well 3 H-thymidine (Amersham, Little Chalfont, UK). After 24 h the cells were harvested on to glass fiber filters by an automated cell harvester (Seamat Ltd, Herts, UK) and 3 H-thymidine incorporation was determined with a liquid scintillation counter (Beckman LS6500; Labplan, Kildare, Ireland). All data are presented as mean c.p.m. from triplicate cultures.
Results
Establishment of high and low Bcr-Abl expressing cell lines
32D cells are IL-3-dependent, diploid, myeloid progenitor cells. They were originally isolated by in vitro culture of murine bone marrow cells 25 and do not spontaneously form growth factor-independent clones. Upon introduction of the Bcr-Abl oncogene, these cells become growth factor independent and are tumorigenic in SCID mice. 26 There is accumulating evidence that the level of the Bcr-Abl protein may contribute to disease progression and drug resistance, therefore we clonally isolated Bcr-Abl transfected cells by serial dilution in the presence of the selecting antibiotic, puromycin. Bcr-Abl expression was analysed by immunoblotting using a monoclonal antibody raised against the C-terminus of ABL. Several clones were isolated which expressed variable levels of Bcr-Abl. Expression levels were assessed in the clones for 6-8 weeks, and remained stable for this time period. Subsequent experiments were carried out only with cells passaged for no longer than 4 weeks. Two clones were selected for detailed characterisation that expressed high (C4) and low levels (C2) of Bcr-Abl ( Figure 1a) .
The kinase activity of Bcr-Abl in high and low expressors was determined by analysing the levels of tyrosine phosphorylation in total cell lysates using SDS PAGE and immunoblotting with an anti-phosphotyrosine antibody (Figure 1b) . Low expression levels of Bcr-Abl (C2 cells) exhibit cellular phosphotyrosine levels far greater than the 32D parental cell line indicative of Bcr-Abl kinase activity. High expressors of Bcr-Abl (C4 cells) have an altered pattern of cellular phosphorylation in addition to further increased levels of tyrosine phosphorylation compared to low expressors. The observation of different phosphorylated proteins distinguishable by molecular weight between C2 and C4 cells, suggests that the substrates of Bcr-Abl can vary depending on the amount of BcrAbl protein present in the cell.
Leukemia
Bcr-Abl tyrosine kinase activity is responsible for growth factor independence
To establish that Bcr-Abl alone was responsible for the transformation of 32D cells, or whether additional secondary mutations were acquired during the cloning procedure offering the cells a survival advantage, we assessed the viability of the high and low Bcr-Abl expressors in the presence of the Abl tyrosine kinase inhibitor STI571. This inhibitor has previously been shown to inhibit the kinase activity of Bcr-Abl and induce apoptosis in Bcr-Abl-positive cells. 27 As Figure 1c shows, incubation of C2 and C4 cells in the presence of STI571 induces apoptosis in the absence of IL-3. This demonstrates that the IL-3 independence observed in C2 and C4 cells is due to the kinase activity of Bcr-Abl. Viability is restored by the re-addition of growth factor demonstrating the reversible dependency for Bcr-Abl in both high and low Bcr-Abl expressors (Figure 1c , see top and centre graphs, black bars). It is also notable that C4 cells require a higher concentration of inhibitor to achieve the same level of death as C2 cells. One m STI571 induces approximately 75% cell death in C2 cells, whereas this level of cell death is only achieved with 3 m in C4 cells. STI571 has also been reported to inhibit related receptor tyrosine kinases; the platelet-derived growth factor (PDGF) receptor and c-kit. However, as STI571 it does not influence the growth or survival of parental 32D cells upon growth factor withdrawal ( Figure 1c , bottom graph); we can rule out the inhibition of these kinases as a significant contributing factor in this study. Our results indicate that a concentration of STI571 which can efficiently kill cells expressing low levels of Bcr-Abl, has a reduced effect in cells expressing high levels of Bcr-Abl, and that increased Bcr-Abl expression is associated with increased resistance to this inhibitor.
Non-autocrine mechanism of IL-3-independent growth
Recent observations suggest that primitive CML cells may grow in the absence of growth factor because of an autocrine production of cytokines. 28, 29 To determine if an autocrine mechanism contributes to the growth factor independence in both C2 and C4 cells, we assessed if the culture media from C4 cells could prevent the apoptosis induced by IL-3 withdrawal in 32D cells. Ten per cent WEHI-CM was withdrawn from 32D media and replaced with 10% conditioned media (CM) or total CM from C4 cells, and failed to block apoptosis (data not shown). It is possible however, that these medium supplements do not contain sufficient concentrations of IL-3 to support 32D parental cells. To eliminate this possibility, a neutralising anti-IL-3 antibody was employed to deplete the culture media of IL-3. The addition of 1.5 g/ml anti-IL-3 antibody to the culture media of 32D cells, induced apoptosis to the same extent as complete IL-3 withdrawal. However, addition of the neutralising antibody to Bcr-Abl transformed cells did not cause any cell death, even at concentrations three-fold higher (Figure 2a ). In addition, this neutralising antibody was unable to block the proliferation of the Bcr-Abl transformed cells as assessed by tritiated thymidine ( 3 H) incorporation (Figure 2b ). These results suggest that the growth factor-independent survival and proliferation of 32D Bcr-Abl cells is supported by a non-autocrine mechanism, or that an intracellular autocrine growth cycle exists, and in regard to the attainment of growth factor independence, there is no dif- ference between the low and high level Bcr-Abl expressing clones.
Increased viability and an altered cell cycle distribution in C4 cells
Several theories have been proposed to explain the myeloid expansion that is observed in CML. These include an increased proliferation rate, unregulated proliferation, prolongation in cellular life span and reduction in apoptosis. 30 However, a number of in vivo studies suggest that CML progenitor cells either have a similar or reduced proliferation rate compared to normal progenitor cells. 31, 32 It was also noted in our assessment of cell proliferation (Figure 2b ) that thymidine incorporation was either analogous to 32D cells (as in C2) or reduced relative to non-Bcr-Abl expressing cells (as in C4). We therefore further investigated the rate of growth and cell cycle profiles in the various cell populations. 32D, C2 and C4 cultures were initiated at the same cell number and counted every 24 h for 3 days (Figure 3a) . 32D cells exhibit a slight increase in rate of population expansion in the initial stages, whereas cell numbers in C2 and C4 cultures approach those of 32D cells in the later stages. Cell cycle distribution was analysed at 12 h intervals. The percentage of cells in G1 and S+G2 phases of the cell cycle was determined and presented as a ratio (Figure 3b) . A significant difference in the cell cycle distribution of C4 cells was observed, with more cells residing in G1 phase and less cells in S+G2 phase, compared to both 32D and C2 cells. However, the cell number in the cultures does not reflect a major decrease in the growth rate, as would be suggested by the cell cycle profile in C4. PI uptake by flow cytometry was therefore performed at each time point to assess the percentage of background cell death in each culture (Figure 3c ). 32D cells exhibit a level of apoptosis between 10 and 20%, and this was moderately reduced in C2 cells. However, C4 cells consistently showed significantly lower background levels cell death in culture (4% or less). These results suggest that high Bcr-Abl levels may reduce the cell cycle kinetics, but the population size is not significantly compromised due to a survival advantage.
Leukemia
High levels of Bcr-Abl are essential for its antiapoptotic function
Recent studies have suggested that the anti-apoptotic activity of Bcr-Abl may require high expression levels of the protein. 21, 22 To determine if the level of Bcr-Abl protein in C2 and C4 cells influences anti-apoptotic properties, we examined their response to the cytotoxic drugs etoposide and doxorubicin. C2 cells exhibit comparable drug sensitivity to the parental 32D cells, and the vector control cells, 32DPuro (Figure 4a and data not shown), with the percentage of apoptotic cells progressively increasing over time. However, C4 cells are resistant to the apoptotic stimulus and do not exhibit a delayed apoptotic response (Figure 4a ). Drug resistance was also evident in other high expressing clones and other cell lines known to express elevated Bcr-Abl (ie K562, that expresses comparable Bcr-Abl levels as C4, data not shown). These findings support a model for a threshold level of BcrAbl expression to protect against drug-induced apoptosis. Furthermore, they suggest that the Bcr-Abl expression level in C2 cells is sufficient for growth factor independence but cannot achieve further anti-apoptotic functions associated with BcrAbl.
Sensitisation by STI571 to drug-induced apoptosis
Having demonstrated that survival of the Bcr-Abl clones requires its kinase activity (Figure 1c ), and to eliminate the possible acquirement of drug resistance through secondary abnormalities, it was investigated whether Bcr-Abl expression per se was responsible for the observed drug resistance. If expression of Bcr-Abl was responsible for drug resistance, it would be expected that moderate inhibition of its kinase activity could sensitise the C4 high expressors to drug-induced cell death. In order to investigate this, titrations were performed using low-dose concentrations of STI571. These concentrations reduced but did not completely remove the tyrosine kinase activity, allowing the assessment of cell death induced by a cytotoxin. C2 and C4 cells in the presence of 0.3 m and 0.6 m STI571, respectively, exhibited reduced tyrosine phosphorylation comparable to the parental cells' endogenous phosphotyrosine pattern (Figure 4b and c) . In the presence of 0.5 m STI571, the phosphotyrosine levels of C4 cells resembled that of untreated C2 cells and therefore drug resistance was assessed at this concentration. The drug resistance of C4 cells was significantly reduced (P Ͻ 0.01) and percentage apoptosis was increased to the level obtained in C2 and 32D parental cells (Figure 4d ). It is notable that C2 cells could also be further sensitised to drug-induced apoptosis when the kinase activity of Bcr-Abl was reduced with 0.3 m STI571, but that STI571 could not further sensitise the parental cells to apoptotic cell death, even when used at concentrations tenfold higher (Figure 4d and data not shown) . These results demonstrate that the drug resistance in this model is attributable to the kinase activity of Bcr-Abl and not secondary mutational events. Moreover, these data also indicate that STI571 can alleviate drug resistance and co-operate with another cytotoxic agent. In addition, the sensitivity of cells expressing low levels of Bcr-Abl can be modulated such that they are more sensitive to cytotoxic drugs than Bcr-Abl-negative, progenitor cells. 
Cells expressing high levels of Bcr-Abl show a transient cell cycle arrest without apoptosis in response to cytotoxic drugs
Studies have suggested that Bcr-Abl-mediated resistance to cytotoxic drugs is associated with G 2 M arrest and rescue from apoptosis at this stage. 33 Dual assessment of cell cycle and apoptosis induced by etoposide (Figure 5 ) revealed a G 2 /M arrest followed by apoptosis in 32D and C2 cells, and remaining cells were arrested in G1. However, C4 cells exhibited only a partial G2 arrest followed by recovery, as cells remain in the cell cycle and continue to progress to G1 with no entry into apoptosis. This demonstrates that cell cycle arrest is released, and rescue from apoptosis is achieved only in cells expressing high levels of Bcr-Abl. These results also support other studies which suggest that G 2 M is a critical decision stage with regard to survival in Bcr-Abl expressing cells.
Expression of apoptotic regulators in Bcr-Abl expressing clones
Previous studies have suggested that co-operation between Bcr-Abl and loss of p53 may lead to a drug-resistant phenotype in CML. 11, 12 Therefore, p53 expression levels were investigated following drug treatment to determine whether high Bcr-Abl expressors were capable of up-regulating WTp53. In addition, the expression of genes which are known to be 5 in m) of the Abl inhibitor, STI571, and 50 g total protein lysates were analysed by immunoblotting (anti-phosphotyrosine) for a reduction in phosphotyrosine levels (indicative of Abl kinase activity). Fifty g of untreated 32D total protein lysate was loaded on each Western blot (lane 6) as a control for Abl kinase activity. The MW in kDa of protein markers is indicated. (d) 32D, C2 and C4 were treated with 5 g/ml VP16 for 24 h in the presence/absence of 0.5 m, 0.3 m and 0.5 m STI571, respectively. Graphical data represent the mean ± s.e.m. (n = 3) of cell death as determined by PI uptake. Statistical analysis was performed using an unpaired Student's t-test (*P Ͻ 0.01 for C4 cells with STI571 alone and STI571 + VP16). transactivated (p21, Bax), or repressed (Bcl-2), by p53 was also assessed. 32D, 32DPuro and C2 cells accumulated p53 protein only in response to a cytotoxic insult induced by etoposide (5 g/ml) and doxorubicin (0.3 g/ml). These cells also up-regulated p21 and Bax and down-regulated Bcl-2 ( Figure 6a, b, c and d) . This is consistent with the cell cycle arrest and apoptosis which was induced in these cells ( Figure 5 ). In contrast, p53, p21 and Bax expression was constitutively high in C4 cells, Bcl-2 expression was low, and these levels were not further altered following a cytotoxic insult (Figure 6a, b, c and d) . Therefore, it appears that due to high expression of Bcr-Abl, p53 is up-regulated and/or stabilised in these cells. The drug resistance of these cells further suggests that high levels of Bcr-Abl are anti-apoptotic despite WTp53 stabilisation, and pro-apoptotic shift in the Bax/Bcl2 ratio.
As other studies have suggested that Bcr-Abl can up-regulate another anti-apoptotic regulator, Bcl-xL, we also assessed Leukemia the expression of this protein as it is possible that this may only be a feature of high Bcr-Abl expressing cells (Figure 6e ). Bcl-xL was up-regulated in both the C2 and C4 Bcr-Abl clones. This suggests that up-regulation of this anti-apoptotic gene may be important for resistance to apoptosis following growth factor withdrawal (ie as both clones are growth factor independent), but that it cannot be solely responsible for the resistance to cytotoxic drugs in C4 cells.
Discussion
Expression of Bcr-Abl in the 32D haematopoietic cell line conferred growth factor independence. A previous study has, however, indicated that complete growth factor independence in the UT-7 cell line is only achieved at moderately high expression levels of Bcr-Abl, and that lower levels just reduce factor dependence. 21 In addition, studies of CML progenitor
Figure 5
Dual measurement of the cell cycle distribution and apoptotic sensitivity in high and low Bcr-Abl expressors (as described in Materials and methods). 32D, C2 and C4 cells were treated with 5 g/ml VP16 and at 12 h intervals assessed for TUNEL labelling (apoptosis) and PI staining (DNA content, indicative of cell cycle phase) by flow cytometry. G1, S and G2 phases of cell cycle are indicated. TUNELpositive cells with a sub-G1 DNA content are also indicated. Data are representative of three individual experiments and numbers in circles indicate percentage apoptosis at the time points indicated. cells (chronic phase) have also suggested that these cells are not growth factor independent. However, CML progenitors undoubtedly have a survival advantage as there is an expanded myeloid progenitor cell population. This may be due to reduced dependence on a combination of survival factors and/or reduced responsiveness to inhibitory signals from stromal cells, as has been previously proposed. 34, 35 As our transfected cell lines no longer require the colonystimulating/survival factor IL-3, they are not therefore, representative of early chronic phase CML but rather a more advanced stage at which their pro-survival/anti-apoptotic nature is considerably enhanced.
As we were primarily interested in investigating mechanisms of drug resistance, the Bcr-Abl expressing clones were selected in the absence of IL-3. In the low expressing clone (C2), IL-3 independence is achieved but drug resistance is not. It is possible that a critical level of Bcr-Abl is required to achieve growth factor independence. If such a level was achieved in vivo this could, in principle, permit progenitor cells to survive at sites where the concentration of survival factors would be extremely low relative to the bone marrow. It is notable that at high white blood cell (WBC) counts in CML, a significant proportion (more than 50%) of the progenitor population can be found at peripheral sites, 36 suggesting a reduction in their requirement for bone marrow survival factors.
In vivo studies have demonstrated other unique properties of CML progenitor cells. Kinetic studies have shown a reduced proportion of cycling cells in an expanded population, and even fewer cycling progenitor cells in the acute phase. 31 Evidently it is not the rate of cell division alone that causes population expansion but the boundaries normally dictated by survival factor concentration have been advanced by a Bcr-Ablmediated reduced dependence. The reason for this reduction in cycling cells is unknown. In our cell line model we have demonstrated that when Bcr-Abl expression is elevated, this causes a reduction in the number of cycling cells, associated with a markedly lower level of background apoptosis during subculture and drug resistance. To our knowledge, this is the first time that a constitutive anti-proliferative effect of Bcr-Abl has been reported in a cell line model.
Studies by Nishii and co-workers 33 demonstrate that a reduction in cell cycling in Bcr-Abl-positive cells is important following treatment with genotoxic damaging agents, and that abrogation of this cell cycle modulation abolishes Bcr-Abl's protective effect. 33 It is possible that in our model the reduction in the proportion of proliferating cells may also contribute to drug resistance. Alternatively, the anti-apoptotic nature of high levels of Bcr-Abl may be due to its capacity to activate pathways common to IL-3 signalling and also additional survival pathways. A previous study has shown that the provision of growth factor (IL-2 and IL-3) or expression of an activated Ras oncogene could not offer the same protection against apoptotic stimuli as high expression of Bcr-Abl. 22 The production of excess IL-3 and GM-CSF in vivo has been reported to contribute to disease progression. 29 However, there is also extensive evidence from in vitro studies that argue against the autocrine secretion of cytokines by Bcr-Abl expressing cells. 26, [37] [38] [39] It has been demonstrated that the presLeukemia ence of an activated tyrosine kinase alone is necessary and sufficient for growth factor independent proliferation. 40 Consistent with other investigators, we observed a non-autocrine mechanism of growth factor-independent proliferation in both high and low Bcr-Abl expressors.
The tyrosine kinase inhibitor, STI571, was cytotoxic to cells expressing high and low levels of Bcr-Abl in the absence of IL-3, indicating that Bcr-Abl alone was responsible for their growth factor independence. It was also notable that the C4 clone requires at least twice the concentration of STI571 to achieve the same level of cytotoxicity. This Bcr-Abl inhibitor has already been evaluated in phase I clinical trials. Chronic phase patients who had been unresponsive to interferon alpha showed an excellent response rate in clinical trials. 41 Response rates for blast crisis phase patients were, however, lower and relapse was common. 42, 43 Longer term follow-up is necessary for many patients and current phase II and III trials will provide more information on dose requirements, toxicity and combination with other standard treatments. Association of increased resistance to STI571 with Bcr-Abl amplification has recently been reported in other cell lines, 44 and in recent clinical studies, resistance to STI571 was associated with elevation of Bcr-Abl expression. 45 Such studies suggest that trials employing this inhibitor may be informative if they also incorporated testing of Bcr-Abl expression levels.
Our study has demonstrated that it is the elevated tyrosine kinase activity which is conferring the drug-resistant phenotype, and that cells expressing high levels of Bcr-Abl can be sensitised to cytotoxic drugs by co-treatment with STI571. A co-operative effect between STI571 and several anti-leukaemic drugs has also been recently reported in two other studies. 46, 47 Furthermore, our study also suggests that when cells are not at a highly resistant stage (as in C2), their sensitivity to cytotoxins can be significantly increased with STI571, whereas non-Bcr-Abl expressing cells are not affected (Figure 4d ). These data combined with other recent data on this inhibitor suggest that regimens which combine STI571 with other drugs have considerable potential, particularly as drug resistance is often a feature of single-agent therapy.
A number of studies have suggested that loss of p53 (a proapoptotic tumour suppressor) can be a major co-operating lesion in Bcr-Abl expressing cells. When 32D, 32DPuro and C2 cells are treated with a cytotoxic insult, they undergo cell cycle arrest in both G1 and G 2 M (Figure 5 ), followed by apoptosis. Stabilisation of p53 and p21 was associated with the cell cycle arrest observed, suggestive of p53 tumour suppressing activity. These cells also up-regulated Bax expression (pro-apoptotic) and down-regulated Bcl-2 expression (antiapoptotic), which are transcriptionally activated and repressed by p53, respectively. 23 In contrast, only a limited cell cycle arrest is observed in C4 cells, and they do not undergo apoptosis. C4 cells notably exhibit elevated p53, p21 and Bax expression and down-regulate Bcl-2 in the absence of a cytotoxic insult. Despite this pro-apoptotic shift in protein expression, these cells are viable and drug resistant. It is possible that this drug resistance may be related to altered cell cycle progression or an inability to engage apoptosis following G 2 /M arrest as previously reported. 33 Although likely to play a role, we do not know if p53 transcriptional activation or repression plays a role in the apoptosis induced in 32D cells, however, the data presented here suggest that loss of p53 is likely to co-operate in the attainment of drug resistance when Bcr-Abl expression is low, in agreement with other studies (see Introduction). In contrast to C2 cells, it is apparent that C4 cells may have nothing to gain from the loss of p53, as the expression of this tumour suppressor protein may reduce entry into the cell cycle but its normal pro-apoptotic activity appears to be of no functional consequence in high Bcr-Abl expressing cells.
The nature of the predominant anti-apoptotic signals in high Bcr-Abl expressing cells remains to be elucidated. Expression of the anti-apoptotic gene Bcl-xL has previously been reported to be increased by Bcr-Abl, and indeed is down regulated by STI571. 48 However in this study we found up-regulation of Bcl-xL in both the drug-sensitive (C2) and drug-resistant (C4) Bcr-Abl expressing cell lines. This suggests that Bcl-xL may play an important role in the attainment of growth factor independence but that it cannot be solely responsible for the drug resistance evident in C4 cells.
In conclusion, this cell line model has demonstrated the importance of Bcr-Abl expression levels in resistance to apoptosis. While other co-operating mutations could potentially play a role in disease progression and the attainment of drug resistance, we have shown that elevated expression of Bcr-Abl alone is sufficient to achieve a drug-resistant state. Notably, elevated expression of Bcr-Abl has already been reported in clinical samples. These observations are of current importance as an inhibitor of Bcr-Abl, STI571, is being assessed in clinical trials. If chronic phase patients express relatively low levels of protein, then in principle, they should respond well to this inhibitor (as suggested by phase I trial results), however, if therapy selects for higher expressing clones, then blast crisis patients are likely to require much higher doses of the inhibitor. Our data further support the potential of combination therapy to alleviate the problem of drug resistance. The primary mechanisms which confer resistance to Bcr-Abl expressing cells remain to be established. It is anticipated that this cell line model will lend insights into the molecular events that impede therapeutic intervention following CML progression.
